Daily Medication Pearl: Tisagenlecleucel (Kymriah)
Medication Pearl of the Day: Tisagenlecleucel (Kymriah)
Indication: Kymriah is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL), adult patients with relapsed or refractory (r/r) large B-cell lymphoma after 2 or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
- Dosing: Administer 0.6 to 6.0 x 108 chimeric antigen receptor (CAR)-positive viable T cells intravenously.
- Dosage form: A single dose of Kymriah contains 0.6 to 6.0 x 108 CAR-positive viable T cells suspended in 1 to 3 patient-specific infusion bag(s) for IV infusion.
- Adverse events (AEs): Common AEs (incidence greater than 20%) are CRS, infectionspathogen unspecified, fever, diarrhea, nausea, fatigue, hypotension, edema, bleeding episodes, dyspnea, and headache.
- Mechanism of action:Kymriah is a CD19-directed genetically modified autologous T cell immunotherapy that involves reprogramming a patient’s own T cells with a transgene encoding a CAR to identify and eliminate CD19-expressing malignant and normal cells.
- Manufacturer: Novartis